Why the study?
Despite advances in antihypertensive therapy, blood pressure control remains suboptimal globally and in Saudi Arabia, with resistant hypertension representing a high-risk phenotype associated with increased cardiovascular and renal morbidity.
This Saudi Heart Association position statement provides a practical stepwise framework to improve the identification, optimize the management, and enhance clinical outcomes in patients with uncontrolled or resistant hypertension.
Answers are grounded in this paper and cite their sources.
Supports implementation of the stepwise framework in practice; extends international consensus with Saudi-specific recommendations.
Background: Despite advances in antihypertensive therapy, blood pressure control remains suboptimal globally and in Saudi Arabia, where uncontrolled hypertension continues to contribute significantly to disease burden. Resistant hypertension represents a high-risk phenotype associated with increased cardiovascular and renal morbidity. Methods: This Saudi Heart Association position statement was developed by a multidisciplinary expert panel using a structured consensus approach and a comprehensive, non-systematic review of the literature. Evidence on epidemiology, pathophysiology, diagnosis, and management of uncontrolled and resistant hypertension was critically appraised to formulate clinically applicable recommendations. Results and conclusions: Uncontrolled and resistant hypertension are driven by complex mechanisms including activation of the renin–angiotensin–aldosterone system, sympathetic overactivity, endothelial dysfunction, and coexisting conditions such as obesity, chronic kidney disease, and obstructive sleep apnea. Accurate diagnosis requires exclusion of pseudo-resistance and secondary causes using standardized blood pressure assessment and out-of-office monitoring. Management should follow a stepwise approach, beginning with lifestyle optimization and foundational triple therapy, followed by pharmacologic intensification with aldosterone-directed therapy or phenotype-guided treatment as needed. Device-based therapies may be considered in selected patients. Emerging treatments targeting key mechanistic pathways, including endothelin signaling and aldosterone synthesis, offer promising future options. This position statement provides a practical stepwise framework to improve identification, optimize management, and enhance clinical outcomes in patients with uncontrolled or resistant hypertension.
No takes yet. Share an insight, caveat, or question.
AlHabeeb et al. (2026) conducted a review in Uncontrolled and resistant hypertension. Stepwise management including lifestyle optimization, foundational triple therapy, aldosterone-directed or phenotype-guided pharmacologic intensification, and device-based therapies was evaluated on Identification, management optimization, and clinical outcomes in uncontrolled or resistant hypertension. Stepwise management starting with lifestyle optimization and triple therapy, followed by aldosterone-directed or device-based treatment, is recommended for uncontrolled and resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: